Years ago, a family member was diagnosed with an extremely rare cancer: Liposarcoma of the Spermatic Cord. Fewer than... The ...

Because liposarcoma is rare, commonly recurs, and has evolving treatments, it cannot be overemphasized that patients should be referred to specialized cancer treatment centers where a larger ...

Boehringer Ingelheim has started a registration trial of its experimental therapy brigimadlin as a treatment for dedifferentiated liposarcoma (DDLPS), a rare cancer with limited treatment options.

The phase 2 trial showed a 42% response rate with lete-cel in synovial sarcoma and MRCLS, with manageable adverse events.

Dalpiciclib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Well Differentiated Liposarcoma.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Oncotarget 10: 8226-43, 2015 Abbas Manji G, Singer S, Koff A, and Schwartz GK. Application of molecular biology to individualize therapy for patients with liposarcoma. Am Soc Clin Oncol Educ Book.

The SU2C-SARC032 study demonstrated that pembrolizumab combined with radiotherapy and surgery was well tolerated, with ...